United States Patent 4,452,774: Scope, Claim Construction, Expiration, and Radiopharmaceutical Patent Landscape

US 4,452,774 covers radioactive-metal isonitrile coordination complexes, kits for preparing those complexes, and imaging methods using technetium-99m isonitrile compounds. Its commercially important subject matter is the technetium-99m isonitrile class associated with myocardial perfusion imaging, including the broader chemical concept underlying technetium-99m sestamibi.

The patent issued June 5, 1984, and, as a pre-Uruguay Round patent subject to the former 17-year term from issuance, expired June 5, 2001, absent an unusual term adjustment or enforceable terminal extension. It therefore does not create current U.S. patent exclusionary rights. Its claims remain relevant for historical freedom-to-operate analysis, patent-family tracing, claim interpretation, and understanding the development of technetium radiopharmaceuticals.

What invention does US 4,452,774 cover?

The patent claims coordination complexes in which an isonitrile ligand binds a radioactive metal through the carbon atom of the isonitrile group. The principal technical concept is a radiometal complex with sufficient lipophilicity and stability for biological localization and gamma-camera imaging.

The claims divide into four groups:

Claim group	Claims	Subject matter
Broad chemical complexes	1-17	Radioactive-metal isonitrile complexes
Preparation kits	18-29	Ligand-plus-reducing-agent kits, including lyophilized sterile kits
Imaging methods	30-35	Tissue imaging and emboli detection using technetium-99m complexes
Cell and liposome labeling	36	Incubation of cells or liposomes with the claimed complexes

The patent is chemically broad at the independent-claim level. Claim 1 reaches a coordination complex of an isonitrile ligand and a radioactive isotope of any metal selected from a long list that includes technetium, rhenium, ruthenium, cobalt, iron, osmium, iridium, chromium, molybdenum, manganese, nickel, rhodium, palladium, niobium, tantalum, tungsten, and platinum.

How broad is claim 1 of US 4,452,774?

Claim 1 has three essential elements:

A coordination complex.
An isonitrile ligand.
A radioactive metal selected from the listed elements.

The claim does not require a particular radionuclide, oxidation state, coordination number, ligand substitution pattern, charge, biodistribution profile, route of administration, or medical indication. It therefore reaches a wide theoretical chemical genus.

Claim 2 narrows claim 1 to technetium. Claim 3 narrows it to rhenium. Claims 4-6 further narrow the ligand to aliphatic, hydrocarbon, or saturated hydrocarbon isonitriles.

Claim 7 requires every coordinate position of the radioactive metal to be filled by an isonitrile ligand. For an octahedral complex, that language supports hexakis-isonitrile species such as:

[Tc(CNR)6]+
[Re(CNR)6]+
Related neutral or anionic complexes with different metal oxidation states and ligand counts

Claim 8 covers monodentate isonitriles. Claims 9 and 10 extend the claim set to bidentate and tridentate isonitrile ligands. Claim 11 covers cationic lipophilic complexes, a commercially important limitation because lipophilicity can influence cell membrane penetration and tissue distribution.

What does claim 15 cover?

Claim 15 is a broad formula claim:

[A((CN)xR)yBzB'z']n

Its principal limitations are:

A is a listed radionuclide.
The isonitrile ligand binds through the carbon atom of the CN group.
R is an organic radical.
B and B' are additional ligands, solvents, halides, or neutral donor ligands.
x and y range from 1 to 8.
z and z' range from zero to seven.
The total coordination number does not exceed eight.
The complex may be neutral, cationic, or anionic.

This claim is broader than a claim limited to a hexakis complex. It can cover mixed-ligand coordination compounds containing one or more isonitrile ligands and other donor ligands.

From an infringement perspective, claim 15 would require detailed structural analysis. Questions would include whether the radiometal is within the listed class, whether the ligand is an isonitrile rather than a nitrile or another carbon donor, whether the ligand is bonded through the isonitrile carbon, and whether the total coordination number satisfies the formula.

What does claim 16 cover?

Claim 16 is directed to:

[A(CNR)6]+

The radionuclide must be technetium or rhenium-188, and R is an organic radical. This is the most direct claim to cationic hexakis-isonitrile complexes.

The claim does not limit R to tert-butyl, isopropyl, methoxyisobutyl, or another specific substituent. A structurally qualifying hexakis complex with technetium or rhenium-188 could fall within the literal scope, subject to the required radionuclide identity and charge.

Claim 17 narrows the subject matter to a cationic lipophilic hexakis tert-butylisonitrile technetium complex. Claims 31, 32, 34, and 35 identify specific imaging embodiments using hexakis tert-butylisonitrile and hexakis isopropylisonitrile complexes.

Does US 4,452,774 cover technetium-99m sestamibi?

Technetium-99m sestamibi is commonly identified as hexakis(2-methoxyisobutyl isonitrile) technetium-99m, also called methoxyisobutylisonitrile or MIBI. It is a cationic technetium complex containing six isonitrile ligands.

At the structural level, sestamibi is closely aligned with the subject matter of claims 1, 2, 7, 8, 11, 15, and 16:

Sestamibi characteristic	Corresponding patent limitation
Technetium radionuclide	Claims 2, 12-16
Isonitrile ligands	Claims 1, 4-10, 15, 16
Six ligands around technetium	Claims 7 and 16
Cationic complex	Claims 11, 15, and 16
Lipophilic complex	Claim 11
Organic substituent on isonitrile	Claims 5, 6, 15, and 16

The patent claims, however, expressly identify tert-butylisonitrile and isopropylisonitrile embodiments, not the methoxyisobutyl ligand used in sestamibi. The broader claims do not depend on those two named embodiments.

The claim analysis is therefore different from the commercial-name analysis. A product need not be called "Cardiolite" or "sestamibi" to fall within a broad chemical claim, while a product using a different ligand may avoid a narrower claim such as claim 17.

What kits are protected by US 4,452,774?

Claims 18-29 cover kits containing:

A predetermined quantity of an isonitrile ligand.
A reducing agent.
A radionuclide or a supply intended to receive a radionuclide.
Components capable of forming the claimed complex.

Claims 19 and 20 narrow the kit to a lyophilized formulation in a sealed, sterilized container. Claims 21 and 22 specify technetium and rhenium embodiments. Claims 23-26 focus on conversion of technetium-99m pertechnetate into a technetium isonitrile complex.

Claim 24 identifies dithionites and stannous salts as reducing agents. In commercial technetium kits, a reducing agent is necessary because generator-produced pertechnetate is generally supplied as technetium in a high oxidation state and must be reduced before complexation.

The kit claims could historically have presented a separate infringement pathway from the compound claims. A manufacturer could avoid a particular composition claim yet still face an issue under a kit claim if it supplied the specified ligand and reducing system in the claimed form.

What imaging methods are protected?

Claims 30-35 cover administering a technetium-99m isonitrile complex to an animal and detecting localization with a gamma camera.

The method claims include:

General body-tissue imaging.
Imaging with hexakis tert-butylisonitrile.
Imaging with hexakis isopropylisonitrile.
Detection of vascular emboli.
Localization of the complex at emboli.

These claims are narrower than the broad composition claims because they require:

A radiopharmaceutical composition.
Technetium-99m.
Administration to an animal.
Gamma-camera detection.
For claims 33-35, detection of vascular emboli.

A product might therefore fall within a composition claim but not a method claim if it is not used in the claimed imaging method. Conversely, clinical use of an otherwise qualifying technetium-99m isonitrile product could implicate the method claims, subject to their expiration.

What does claim 36 cover?

Claim 36 covers labeling a cell or liposome by incubating it with a qualifying radioactive-metal isonitrile complex in a suitable medium.

This claim is distinct from the imaging claims. It does not require administration to an animal or gamma-camera detection. Its subject matter includes ex vivo or in vitro labeling applications involving cells or liposomes.

The claim could have been relevant to research tools, cellular tracking, liposome biodistribution, and diagnostic assay development. It does not appear directed specifically to myocardial perfusion imaging.

When did US 4,452,774 lose exclusivity?

Event	Date
Filing date	Patent-family record required for exact priority analysis
Issue date	June 5, 1984
Standard pre-URAA expiration	June 5, 2001
Current enforceability	Expired
Current Orange Book patent exclusivity from this patent	None
Current Paragraph IV significance	None for this expired patent

The patent issued before June 8, 1995, and therefore falls under the former 17-year-from-issuance term rather than the 20-year-from-earliest-effective-filing term generally applicable to later applications. The expiration date is consequently based on the issue date, subject to any terminal disclaimer, reexamination adjustment, or other record-specific modification. Patent term extension under 35 U.S.C. § 156 is generally associated with approved drug products and must be checked separately from the ordinary patent term.

No current U.S. exclusivity should be attributed to US 4,452,774.

What is the Orange Book status of US 4,452,774?

US 4,452,774 is not a current source of Orange Book exclusivity because it expired in 2001. Orange Book listing status is product-specific and depends on the NDA holder’s patent certifications and the FDA’s treatment of listed patents. A historical listing, if any, would not restore enforceability after expiration.

For technetium-99m sestamibi products, current commercial risk is more likely to arise from:

Manufacturing approvals.
Drug-master-file controls.
Product-specific regulatory requirements.
Current formulation or device patents.
Trade secrets relating to kit manufacture.
Supply and distribution arrangements.
Regulatory exclusivity, if applicable.

The expired patent remains relevant as prior art and as a historical family member, but it is not a current Orange Book barrier.

Which companies commercialized products related to this patent?

The commercial history of technetium-99m isonitrile imaging agents is associated with the University of Washington technology program, DuPont, and later Bristol-Myers Squibb commercial operations. Cardiolite became the principal commercial product associated with technetium-99m sestamibi. FDA labeling identifies Cardiolite as a technetium Tc 99m sestamibi kit for preparation of the diagnostic radiopharmaceutical (U.S. Food and Drug Administration, n.d.).

The commercial chain illustrates the distinction between patent ownership, licensing, and product marketing:

Participant	Historical role
University of Washington researchers	Development and originating institutional technology
DuPont	Commercial development and marketing of Cardiolite
Bristol-Myers Squibb	Later ownership or commercialization of DuPont pharmaceutical assets
Radiopharmacy and generic-kit companies	Manufacture or distribution of technetium-99m sestamibi kits

The patent itself does not establish that every later product was licensed under the same agreement. Licensing rights, assignments, and product commercialization rights must be traced through the patent assignment record, SEC filings, transaction documents, and FDA application history.

What competing radiopharmaceutical patent estates matter?

The principal commercial comparator is technetium-99m tetrofosmin, marketed in the United States as Myoview. Tetrofosmin is a different technetium complex and is not an isonitrile compound. It competes with sestamibi in myocardial perfusion imaging but does not ordinarily fall within the isonitrile-specific claims of US 4,452,774.

Product	Active radiopharmaceutical	Relation to US 4,452,774
Cardiolite	Technetium Tc 99m sestamibi	Directly related to the claimed technetium isonitrile class
Generic sestamibi kits	Technetium Tc 99m sestamibi	Directly related chemically, but the patent is expired
Myoview	Technetium Tc 99m tetrofosmin	Competitive product; different ligand class
Thallous chloride Tl 201	Thallium-201 chloride	Alternative myocardial perfusion agent; outside the claimed isonitrile class

The principal current competitive issue is not whether tetrofosmin infringes US 4,452,774. Its chemistry is materially different. The commercial question is whether a manufacturer can produce and obtain approval for a sestamibi kit at competitive cost, with reliable radionuclide supply and validated quality controls.

How strong was the patent estate?

The patent had substantial breadth on its face but several potential validity and enforcement pressure points.

Strengths

Claim 1 covered a large set of radioactive metals.
Claim 15 covered mixed-ligand complexes through a broad coordination formula.
Claim 16 directly targeted cationic hexakis technetium and rhenium complexes.
Claims 18-29 covered kit architecture, not only the final compound.
Claims 30-35 covered clinical imaging methods.
Claim 36 extended to cell and liposome labeling.

Potential limitations

The metal genus was unusually broad.
The ligand genus extended across many isonitrile structures.
Enablement and written-description questions could arise for combinations not specifically exemplified.
Some listed radionuclides and complexes may have different coordination chemistry, oxidation-state behavior, stability, or radiopharmaceutical utility.
Claim 15 contains complex formula and coordination-number limitations that could create claim-construction disputes.
Claims 17, 31, 32, 34, and 35 are narrower and depend on specific ligand embodiments.
The patent’s commercial value ended when the patent expired.

The estate was strongest against products closely matching the disclosed technetium hexakis-isonitrile concept. It was weaker as a practical basis for asserting every possible radioactive-metal/isonitrile combination.

What generic launch risks exist today?

For a new U.S. technetium-99m sestamibi kit, US 4,452,774 presents no current patent launch block. A generic or competing product would instead face:

FDA drug-product requirements for radiopharmaceutical kits.
Chemistry, manufacturing, and controls requirements.
Sterility and container-closure controls.
Radionuclide labeling and radiochemical-purity specifications.
Validation of reconstitution and shelf life.
Supply-chain risks for molybdenum-99/technetium-99m.
Potential current patents unrelated to the expired compound patent.
State and federal radiopharmacy requirements.
Competition from established kit manufacturers and radiopharmacy distributors.

A Paragraph IV challenge to US 4,452,774 would have no present commercial value because the patent is expired. Any current Paragraph IV strategy would target later unexpired patents listed for a specific reference product, not this patent.

Does biosimilar law apply?

No. Technetium-99m sestamibi is a chemically defined small-molecule radiopharmaceutical, not a biologic subject to the biosimilar pathway under the Biologics Price Competition and Innovation Act.

The applicable competitive framework is the small-molecule generic-drug and abbreviated application system, with product-specific FDA requirements for radiopharmaceutical kits. The relevant approval route depends on the reference product, dosage form, formulation, labeling, and FDA determination of pharmaceutical equivalence.

What manufacturing and intellectual-property barriers remain?

The expired patent does not eliminate manufacturing barriers. Technetium-99m kits require controlled production of the ligand and excipients, validated reduction chemistry, sterile packaging, and reliable reconstitution performance.

Important technical controls include:

Ligand identity and purity.
Control of technetium oxidation state.
Radiochemical purity.
Stability after reconstitution.
Sterility and endotoxin control.
Container-closure integrity.
Reproducibility across generator eluate conditions.
Performance over the labeled shelf life.

The practical barrier is often operational rather than patent-based. A competitor must meet radiochemical specifications consistently despite short radionuclide half-life, decentralized preparation, generator variability, and time-sensitive distribution.

Key Takeaways

US 4,452,774 covers radioactive-metal isonitrile complexes, preparation kits, technetium-99m imaging methods, emboli detection, and cell or liposome labeling.
Claims 1, 2, 7, 11, 15, and 16 are the principal claims relevant to technetium-99m hexakis-isonitrile compounds.
Technetium-99m sestamibi is structurally aligned with the patent’s broad technetium, cationic, lipophilic, and hexakis-isonitrile claims.
The patent issued June 5, 1984, and its ordinary patent term expired June 5, 2001.
The patent provides no current U.S. patent exclusivity or Paragraph IV barrier.
Claims 18-29 historically addressed lyophilized sterile kits containing isonitrile ligands and reducing agents.
Claims 30-35 addressed gamma-camera imaging, including tissue imaging and vascular-emboli detection.
Myoview, based on technetium-99m tetrofosmin, is a competitive product with a different ligand class.
Current sestamibi launch risk is driven primarily by FDA requirements, manufacturing controls, supply logistics, and any later product-specific rights.

Frequently Asked Questions

Is US 4,452,774 still enforceable?

No. The patent’s ordinary term expired in 2001.

Does Cardiolite still have patent protection from this patent?

No. Any current protection for a Cardiolite or sestamibi product would have to arise from later patents, regulatory exclusivity, trade secrets, or commercial arrangements.

Is technetium-99m sestamibi a biologic?

No. It is a chemically defined small-molecule radiopharmaceutical kit.

Could a generic sestamibi kit infringe claim 16?

The chemical structure of sestamibi is within the general structural concept of a cationic technetium hexakis-isonitrile complex. Claim 16, however, expired and cannot create current infringement liability.

Does US 4,452,774 cover technetium-99m tetrofosmin?

Not on the claim language supplied. Tetrofosmin is not an isonitrile ligand complex and is chemically distinct from the claimed class.

References

U.S. Patent No. 4,452,774. (1984). Radiopharmaceuticals and methods of preparing and using same. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (n.d.). CARDIOLITE: Kit for the preparation of technetium Tc 99m sestamibi injection. FDA-approved prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
United States Code, 35 U.S.C. §§ 154, 156, 271, 282. (2024). Patent term, patent-term extension, infringement, and validity provisions.
United States Patent and Trademark Office. (n.d.). Patent term calculator and patent term guidance. USPTO.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0107734	⤷ Start Trial	SPC/GB93/166	United Kingdom	⤷ Start Trial
European Patent Office	0107734	⤷ Start Trial	93C0042	Belgium	⤷ Start Trial
Austria	28568	⤷ Start Trial
Canada	1218666	⤷ Start Trial
Germany	3372709	⤷ Start Trial
Denmark	172154	⤷ Start Trial
Denmark	257183	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,452,774

Summary for Patent: 4,452,774